Figure 2.
Kaplan–Meier estimates of efficacy end points. (A) Investigator-assessed PFS. (B) Investigator-assessed EFS. (C) OS. (D) DFS (intention-to-treat population). Data cutoff: 28 June, 2021. EFS, EFS for efficacy purposes.
Kaplan–Meier estimates of efficacy end points. (A) Investigator-assessed PFS. (B) Investigator-assessed EFS. (C) OS. (D) DFS (intention-to-treat population). Data cutoff: 28 June, 2021. EFS, EFS for efficacy purposes.
